CDC U-turns previous decision on AZ’s flu vaccine
pharmafile | February 22, 2018 | News story | Sales and Marketing | AstraZeneca, Vaccine, biotech, drugs, flu, influenza, pharma, pharmaceutical
The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for the coming flu seasons.
The decision is likely too late for the next winter season, with most stocks of vaccine having already been ordered in, but could see the quadrivalent vaccine used after that.
The decision marks a serious turnaround, after the last two seasons the CDC had advised against ordering the vaccine, due to a long-term study showing that it proved ineffective against the swine flu outbreak.
At one time, AZ’s vaccine had been the go-to option for young children because it meant that any child fearing an injection could easily receive the nasal spray-form of immunisation. It led to a dominant position in the market for AZ, with the product accounting for approximately a third of vaccinations for influenza.
However, once the CDC revealed that large studies had suggested that FluMist was only 3% effective, it was no longer recommended and sales plummeted.
As a result, AZ reformulated the vaccine with a different production method and returned to the CDC; the CDC delivered a 12-2 vote in favour of renewed recommendation and availability of the drug.
Gregory Keenan, Vice President, US Medical Affairs, AstraZeneca, said: “This study validates the improvements we’ve made to our strain selection process and confirms an improved H1N1 LAIV strain was included in the 2017-2018 formulation. We are pleased that the ACIP has voted in support of a renewed recommendation for FluMist Quadrivalent in the US and look forward to continuing to work with public health authorities to optimize protection against influenza.”
The recommendation was not entirely unequivocal – due to the data AZ presented not being based on evidence from the previous two flu seasons.
This was no fault of AZ, the protection offered by FluMist protects against the H1N1 strain of influenza whilst the last two seasons have been dominated by other variants, including the H3N2 strain that has proved particularly problematic this season, globally.
Ben Hargreaves
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
